AJMC® in the Press, November 6, 2026

The study “Electronic Health Record Problem Lists: Accurate Enough for Risk Adjustment?,” published in The American Journal of Managed Care^® (AJMC^®) in January 2018, compared electronic health record problem lists with clinicians’ notes for 1596 veterans with prostate cancer. The problem lists captured only 23% of congestive heart failure, 42% of chronic obstructive pulmonary disease, and 46% of diabetes cases, and only comorbidity scores from clinical notes predicted long-term mortality.

Equipo Health, a New Jersey health care technology company, cited the study in a November 2026 press release arguing that diagnosis codes often miss patient risk documented elsewhere in the medical record. The company uses the AJMC findings as its lead evidence to promote its AI Risk Analyzer Engine, which scans unstructured clinical notes for coding gaps and undocumented conditions.

The article “New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence,” published on AJMC.com in October 2026 covered 2 PrEPFACTS claims analyses presented at the Academy of Managed Care Pharmacy Nexus 2026 meeting. In the first analysis, just 5 of 2913 people who received long-acting cabotegravir (CAB LA) showed evidence of HIV during follow-up, and 2 of the new cases had stopped CAB LA months before testing positive. In the second, 40% of CAB LA users maintained sustained high adherence over their first year compared with 26% of people on oral preexposure prophylaxis.

Gayety, an LGBTQ+ news and lifestyle site, cited the AJMC.com article in an October 2026 story on the ViiV-funded studies of Apretude, the branded version of CAB LA. The story noted that these were conference findings from claims data, and then turns to insurance barriers to injectable preexposure prophylaxis (PrEP). For that part, it quoted the AJMC.com article, “Insurance Barriers Tied to Missed Long-Acting PrEP Starts,” on a St. Louis study in which 4 in 10 patients prescribed injectable PrEP never received it.

The article, “Occasional Cannabis Use Linked to 40% Higher Odds of Stroke,” published on AJMC.com in November 2026, covered a poster abstract that is set for presentation at the American Heart Association Scientific Sessions 2026. From among survey data from nearly 443,000 US adults, compared with no use, using cannabis 1 to 5 days a month was linked to 40% higher odds of reported stroke and heavy use was linked to 25% higher odds. There was no significant association with heart attack.

Eastern Herald, an independent global news site, cited AJMC’s coverage in a November 2026 story on the study’s limitations. It noted that the AHA release gave neither confidence intervals nor results for the moderate-use group and argued that without those, readers can’t judge how precise the estimates are or whether risk rises with frequency of use.